- AU$272.31m
- AU$1.20bn
- AU$1.37bn
Citi ups Australia's Healius to 'neutral' rating, sees special dividend on the cards
Jefferies notes Healius' positive outlook for its pathology business
Media: Affinity Equity receives A$515 million leveraged loan from ING Bank for Lumus deal- Bloomberg News
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Australia's Healius jumps on $657 mln sale of diagnostic imaging arm
Australia's Healius jumps on agreement to sell diagnostic imaging arm
Australia's Healius to sell diagnostic imaging arm to Affinity for $657 million (updated)
Australia's Healius to sell diagnostic imaging arm for $657 million
Brief: Healius Announces Sale Of Lumus Imaging To Affinity Equity Partners
Brief: Perpetual Decreases Voting Power In Healius To 14.505% From 15.536% - Exchange Filing
Brief: Healius Says Volume Growth In Pathology Has Continued During July And August
Brief: Healius Posts FY Net Loss AUD 645.8 Mln
Aussie healthcare stocks set to log modest gains in first-half 2024
Morningstar positive on long-term prospects of Australia's Healius despite forecast cut
Brief: Healius Sees Underlying FY 2024 Earnings Before Interest And Tax Of Between A$60 Mln - A$65 Mln
Australia's Healius slips on downgrading FY24 earnings guidance
Brief: Healius Updates On Strategic Review And Appoints Kate Mckenzie As Chair
Jefferies sees Aussie pathology lab chain Healius missing annual outlook